Gesellschaft Zur Forderung Des Wissenschaftlich Medizinischen Erkenntnisgewinns In Der Hamatologie Und Oncologie — Clinical Trial Site

21 Registered trials

9 Currently recruiting

Organisation

Gesellschaft Zur Forderung Des Wissenschaftlich Medizinischen Erkenntnisgewinns In Der Hamatologie Und Oncologie

Location

Muenster, Germany

Identifier

ORG-100041208

Address

Dueesbergweg 128, Dueesberg, 48153, Germany

Departments

GEHO Münster
Gemeinschaftspraxis für Haemato.-,Onkologie und Palliativmedizin
Gemeinschaftspraxis für Hämatologie und Onkologie
Gemeinschaftspraxis für Hämatologie und Onkologie Münster
Haematology and Onkology
Hamatologie Und Oncologie
Hämatologie und Onkologie
hematology
Hematology and Oncology and Internal Medizin
Hematology, Oncology
Hematology/Oncology
Mesotheliomeinheit
N/A
NA
not applicable
Studienzentrale
Überörtliche Gemeinschaftspraxis für Hämatologie und Onkologie

Clinical trials at this site (21)

Search interface

A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending

2024-512195-35-00 Stage I adenocarcinoma non-small cell lung cancer (NSCL 5
A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Pending

2025-523544-12-00 Myelodysplastic neoplasms/syndromes (MDS) 5
Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Pending

2025-523947-36-00 Sub-study 5: Unresectable Pleural Mesothelioma (Volrust 4
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre… Recruiting

2025-524366-21-00 treatment-naive Chronic Lymphocytic Leukemia 5 2026-04-29
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting

2024-519152-82-00 Relapsed/Refractory Follicular Lymphoma 5 2025-09-03
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa… Recruiting

2022-500305-40-00 Small Lymphocytic Lymphoma 9 2024-04-10
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Myelodysplastic Syndrome (MDS) 5 2023-10-11
ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma Ended

2023-505054-17-00 metastatic TTF-1 negative lung adenocarcinoma 6 2023-09-15
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early… Ended

2024-512980-29-00 T1-T2N0 esophageal adenocarcinoma including gastroesoph 4 2023-08-28
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c… Ended

2024-511169-12-00 Non-Small Cell Lung Cancer 5 2023-03-28
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 5 2019-02-11
Obinutuzumab in marginal zone lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (OLYMP-1) Ended

2024-517476-38-00 Marginal Zone Lymphoma 4 2018-05-14
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04